Saturday 17 October 2026 Export BCRX’s income statement to Excel — free account

BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

7.79 0.23 −2.87%

Follow BCRX

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −3.5×
Dividend yield: —
F-score: 7/9
Altman Z: 1.83
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio Full definition →	0.00	0.00	6.24	0.00	+8 more quarters Free account
P/S ratio Full definition →	2.71	2.60	1.87	2.66
P/FCF ratio Full definition →	6.81	7.42	4.74	33.33
P/Operating CF Full definition →	24.39	(37.32)	5.61	38.32
P/B ratio Full definition →	0.00	0.00	0.00	0.00
Price to Tangible BV Full definition →	0.00	0.00	0.00	0.00
EV/Sales Full definition →	3.22	3.30	2.11	3.43
EV/EBITDA Full definition →	0.00	0.00	5.45	28.78
EV/Operating CF Full definition →	8.06	9.35	5.31	40.93
EV/FCF Full definition →	8.11	9.41	5.34	42.94
Quick Ratio Full definition →	2.22	1.78	1.95	1.60
Current Ratio Full definition →	2.32	1.91	2.06	1.87
Net Debt/EBITDA Full definition →	4.92	(0.89)	0.79	16.28
Debt/Assets Full definition →	150.47%	184.94%	93.53%	150.73%
Debt/Equity Full definition →	(1.85)	(1.55)	(4.04)	(1.73)
Asset Turnover Full definition →	1.85	1.87	1.74	1.28
Operating CF/Net income Full definition →	1.33	0.09	1.19	3.23
Capex/Depreciation Full definition →	(0.70)	(0.28)	0.36	0.98
Interest Coverage Full definition →	4.54	(35.47)	18.42	1.51
Research and Development Expense of Revenue Full definition →	23.81%	38.56%	10.05%	27.98%
Selling, General and Administrative Expense of Revenue Full definition →	29.31%	60.45%	23.56%	52.08%
Intangible Assets out of Total Assets Full definition →	0.00	0.00	0.00	0.00
Share Based Compensation of Revenue Full definition →	6.73%	10.25%	5.85%	11.67%
Graham Net Nets Full definition →	(0.21)	(0.28)	(0.14)	(0.30)
Graham Number Full definition →	7.61	9.43	0.00	1.44
Earnings Yield Full definition →	(14.40%)	(18.17%)	16.03%	(0.66%)
Free Cash Flow Yield Full definition →	14.69%	13.48%	21.10%	3.00%
Revenue per Share Full definition →	0.86	0.65	1.94	0.76
Operating CF per Share Full definition →	0.41	(0.26)	1.39	0.20
Capex per Share Full definition →	0.00	0.00	0.00	(0.01)
Free Cash Flow per Share Full definition →	0.41	(0.26)	1.39	0.19
Cash per Share Full definition →	1.39	0.99	1.31	1.02
Shareholders Equity per Share Full definition →	(1.79)	(2.29)	(0.57)	(1.85)
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	(1.79)	(2.29)	(0.57)	(1.85)
Free Cash Flow Full definition →	104.13	(62.19)	291.71	40.28
Working Capital Full definition →	275.84	178.23	208.28	165.45
Capital Expenditures Full definition →	(0.21)	(0.40)	(0.25)	(1.34)
Net Current Asset Value Full definition →	(527.46)	(645.27)	(228.96)	(478.63)
EV/EBIT Full definition →	0.00	0.00	5.41	27.00
Capex to Sales Full definition →	0.00	0.00	0.00	0.01
Price to Operating Income Full definition →	0.00	0.00	4.80	20.96
Other line items
Average Receivables Full definition →	100.97	101.33	92.94	81.89
Average Payables Full definition →	10.02	10.50	13.74	9.52
Average Inventory Full definition →	5.55	6.43	6.74	6.40
Average Assets Full definition →	507.52	472.55	502.29	468.84
Average Common Equity Full definition →	(437.94)	(502.88)	(297.54)	(428.23)

Fold the line items

Columns are period end dates

Stockrow Weekly